NEW YORK, NY / ACCESSWIRE / November 8, 2017 / U.S. markets retreated from their record highs Tuesday on mixed earnings and falling bond yields. The Dow Jones Industrial Average gained 0.04 percent to close at 23,557.23, while the S&P 500 Index fell 0.02 percent to close at 2,590.64. The NASDAQ Composite Index dropped 0.27 percent to close at 6,767.78. Financial stocks were hit the hardest Tuesday as the Financial Select Sector SPDR Fund declined 1.38 percent. The yield on the benchmark 10-year Treasury note dropped to 2.309 percent, from 2.318 percent Monday.
RDI Initiates Coverage on:
Exact Sciences Corporation
Gilead Sciences, Inc.
Exact Sciences Corporation's stock moved 3.81% higher Tuesday, to close the day at $60.50. The stock recorded a trading volume of 3,082,703 shares, which was above its three months average volume of 1,574,690 shares. In the last year, Exact Sciences Corporation's shares have traded in a range of 13.05 - 60.80. The share price has gained 363.60% from its 52-week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $48.55 is greater than its 200-day moving average of $39.38. Shares of Exact Sciences have gained roughly 24.41 percent in the past month and are up 352.84 percent year-to-date.
Access RDI's Exact Sciences Corporation Research Report at:
On Tuesday, shares in Gilead Sciences, Inc. recorded a trading volume of 7,824,337 shares, which was below the three months average volume of 9,475,730 shares. The stock ended the day 1.15% higher at 73.21. The stock is currently trading 14.82% above its 52-week high with a 52-week trading range of 63.76 - 86.27.The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $80.43 is greater than its 200-day moving average of $73.48. Shares of Gilead Sciences, Inc. are trading at a Price to Earnings ratio of 7.95. Shares of Gilead Sciences have fallen roughly 10.87 percent in the past month and are up 2.23 percent year-to-date.
Access RDI's Gilead Sciences, Inc. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.